Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 2Smoldering Multiple Myeloma 1Recurrence 1Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia 1Hodgkin Disease 1

Interventions

Dexamethasone 109pomalidomide 53Cyclophosphamide 52Bortezomib 42fludarabine phosphate 33Lenalidomide 33Peripheral Blood Stem Cell Transplantation 28carfilzomib 26Mycophenolic Acid 25daratumumab 24Calcium Dobesilate 24Cyclosporine 22Busulfan 21Antilymphocyte Serum 20Tacrolimus 19Whole-Body Irradiation 18Melphalan 17Radiotherapy 15Filgrastim 15Methotrexate 14fludarabine 12Methylprednisolone 12elotuzumab 11Cord Blood Stem Cell Transplantation 11selinexor 10ixazomib 9Etoposide 8Thalidomide 7Prednisone 7Panobinostat 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Absorptiometry, Photon × Plasma cell × Clear all
NCT00401011 2018-02-23

Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients

AEterna Zentaris

Phase 1/2 Completed
84 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡